Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk

JAMA

Volumn 276, Issue 18, 1996, Pages 1494-1501

  Ambrosone, Christine B ^a,b   Freudenheim, Jo L ^b   Graham, Saxon ^b   Marshall, James R ^b   Vena, John E ^b   Brasure, John R ^b   Michalek, Arthur M ^b   Laughlin, Rosemary ^b   Nemoto, Takuma ^c   Gillenwater, Kari A ^d   Harrington, Anita M ^d   Shields, Peter G ^d  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 3042828081     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.18.1494     Document Type: Article

References (77)

1. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1989.
2. Adami HO, Lund E, Bergstrom R, Meirik O. Cigarette smoking, alcohol consumption and risk of breast cancer in young women. Br J Cancer. 1988; 58:832-837.
3. Ewartz M. Smoking and breast cancer risk in Denmark. Cancer Causes Control. 1990;1:31-37.
4. Field NA, Baptiste MS, Nasca PC, Metzger BB. Cigarette smoking and breast cancer. Int J Epidemiol. 1992;21:842-848.
5. London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner BA, Speizer FE. Prospective study of smoking and the risk of breast cancer. J Natl Cancer Inst. 1989;81:1625-1631.
6. Rosenberg L, Schwingl PJ, Kaufman DW, et al. Breast cancer and cigarette smoking. N Engl J Med. 1984;310:92-94.
7. Baron JA, Byers T, Greenberg ER, Cummings KM, Swanson M. Cigarette smoking in women with cancers of the breast and reproductive organs. J Natl Cancer Inst. 1986;77:677-680.
8. Doll R, Gray R, Hafner B, Peto R. Mortality in relation to smoking: 22 years' observations on female British doctors. BMJ. 1980;280:967-971.
9. Hiatt RA, Klatsky AL, Armstrong MA. Alcohol consumption and the risk of breast cancer in a prepaid health plan. Cancer Res. 1988;48:2284-2287.
10. Schatzkin A, Carter CL, Green SB, et al. Is alcohol consumption related to breast cancer? results from the Framingham Heart Study. J Natl Cancer Inst. 1989;81:31-35.
11. Schecter MT, Milller AB, Howe GR, Baines CJ, Craib KJ, Wall C. Cigarette smoking and breast cancer: case-control studies of prevalent and incident cancer in the Canadian National Breast Screening Study. Am J Epidemiol. 1989;130:213-220.
12. Vatten LJ, Kvinnsland S. Cigarette smoking and risk of breast cancer: a prospective study of 24,329 Norwegian women. Eur J Cancer. 1990:26: 830-833.
13. Morabia A, Bernstein M, Heritier S, Khatchatrian N. Relation of breast cancer with passive and active exposure to tobacco smoke. Am J Epidemiol. 1996;143:918-928.
14. Stockwell HG, Lyman GH. Cigarette smoking and the risk of female reproductive cancers. Am J Obstet Gynecol. 1987;157:35-40.
15. Chu SY, Stroup NE, Wingo PA, Lee NC, Peterson HB, Gwinn ML. Cigarette smoking and the risk of breast cancer. Am J Epidemiol. 1990;131: 244-253.
16. Brinton LA, Schairer C, Stanford JL, Hoover RN. Cigarette smoking and breast cancer. Am J Epidemiol 1986;123:614-622.
17. Meara J, McPherson K, Roberts M, Jones L, Vessey M. Alcohol, cigarette smoking and breast cancer. Br J Cancer. 1989;60:70-73.
18. Brownson RC, Blackwell CW, Pearson DK, Reynolds RD, Richens JW Jr, Papermaster BW. Risk of breast cancer in relation to cigarette smoking. Arch Intern Med. 1988;148:140-144.
19. Rohan TE, Baron JA. Cigarette smoking and breast cancer. Am J Epidemiol. 1989;129:36-42.
20. Palmer JR, Rosenberg L, Clarke E, et al. Breast cancer and cigarette smoking: a hypothesis. Am J Epidemiol. 1991;134:1-13.
21. Hiatt RA, Fireman BH. Smoking, menopause, and breast cancer. J Natl Cancer Inst. 1986;76:833-838.
22. Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer: final report of an epidemiological study. Br J Cancer. 1983; 47:455-462.
23. O'Connell DL, Hulka BS, Chambless LE, Wilkinson WE, Deubner DC. Cigarette smoking, alcohol consumption, and breast cancer risk. J Natl Cancer Inst. 1987;78:229-234.
24. Salber EJ, Trichopoulos D, MacMahon B. Lactation and reproductive histories of breast cancer patients in Boston, 1965-1966. J Natl Cancer Inst. 1969;43:1013-1024.
25. Petrakis NL, Gruenke LD, Beelen TC, Castagnoli N Jr, Craig JC. Nicotine in breast fluid of nonlactating women. Science. 1978;199:303-304.
26. Petrakis NL, Maack CA, Lee RE, Lyon M. Mutagenic activity in nipple aspirates of human breast fluid. Cancer Res. 1980;40:188-189.
27. Perera FP, Estabrook A, Hewer A, et al. Carcinogen-DN A adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev. 1995;4:233-238.
28. Li D, Wang M, Dhingra K, Hittleman WM. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res. 1996;56:287-293.
29. Swaminathan S, Frederickson SM, Hatcher JF. Metabolic activation of N-hydroxy-4-acetylaminobiphenyl by cultured human breast epithelial cell line MCF 10A. Carcinogenesis. 1994;15:611-617.
30. Eldridge SR, Gould MN, Butterworth BE. Genotoxicity of environmental agents in human mammary epithelial cells. Cancer Res. 1992;52:5617-5621.
31. Tonelli QJ, Custer RP, Sorof S. Transformation of cultured mouse mammary glands by aromatic amines and amides and their derivatives. Cancer Res. 1979;39:1784-1792.
32. Shirai T, Fysh FM, Lee M-S, Vaught JB, King CM. Relationship of metabolic activation of N-hydroxy-N-acylarylamines to biological response in the liver and mammary gland of the female CD rat. Cancer Res. 1981;41:4346-4353.
33. Allaben WT, Weeks CE, Weis CC, Burger GT, King CM, Rat mammary gland carcinogenesis after local injection of N-hydroxy-N-acyl-2-aminofluorenes: relationship to metabolic activation. Carcinogenesis. 1982;3:233-240.
34. Kadlubar FR, Butler MA, Kaderlik KR. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect. 1992;98:69-74.
35. Minchin RF, Kadlubar FF, Ilett KF. Role of acetylation in colorectal cancer. Mutat Res. 1993; 290:35-42.
36. Bell DA, Taylor JA, Butler MA, et al. Genotype/ phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993;14:1689-1692.
37. Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 1994;369:154-156.
38. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet. 1993;52:827-834.
39. Hanssen HP, Agarwal HW, Goedde H, et al. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Eur Urol. 1985;11:263-266.
40. Cartwright RA. Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia. In: Omenn GS, Gelboin HV, eds. Genetic Variability in Responses to Chemical Exposure. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1984:359-368.
41. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylator phenotype in colorectal carcinoma. Cancer Res. 1987;47:1466-1469.
42. Lang NP, Chu DZJ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine N-acetyltransferase in human colorectal cancer. Arch Surg. 1986;121:1259-1261.
43. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prevention. 1994;3:675-682.
44. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA, Pavlova MV. Acetylator phenotype in patients with breast cancer. Oncology. 1978;35:185-188.
45. Evans DAP. Acetylation. Prog Clin Biol Res. 1986;214:209-242.
46. Sardas S, Cod I, Sardas OS. Polymorphic N-acetylation capacity in breast cancer patients. Int J Cancer. 1990;46:1138-1139.
47. Philip PA, Rogers HJ, Millis RR, Rubens RD, Cartwright RA. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol. 1987;23:1701-1706.
48. Ladero JM, Fernandez MJ, Palmeiro R, et al. Hepatic acetylator polymorphism in breast cancer patients. Oncology. 1987;44:341-344.
49. Graham S, Hellmann R, Marshall J, et al. Nutritional epidemiology of postmenopausal breast cancer in western New York. Am J Epidemiol. 1991; 134:552-566.
50. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995;5:1-17.
51. Begg CB, Zhang ZF. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev. 1994;3:173-175.
52. Piergorsch WW, Weinberg CR, Taylor JA. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med. 1994;13:153-162.
53. Wang CY, Yamada H, Morton KC, Zukowski K, Lee M-S, King CM. Induction of repair synthesis of DNA in mammary and urinary bladder epithelial cells by N-hydroxy derivatives of carcinogenic arylamines. Cancer Res. 1988;48:4227-4232.
54. King CM, Traub NR, Lortz ZM, Thissen MR. Metabolic activation of arylhydroxamic acids by N-O-acyltransferase of rat mammary gland. Cancer Res. 1979;39:3369-3372.
55. Allaben WT, Weis CC, Fullerton NF, Beland FA. Formation and persistence of DNA adducts from the carcinogen N-hydroxy-2-acetylaminofluorene in rat mammary gland in vivo. Carcinogenesis. 1983;4:1067-1070.
56. International Agency for Research on Cancer. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Part 1. Lyon, France: International Agency for Research on Cancer, 1972: 74-79.
57. Sadrieh N, Davis CD, Snyderwine EG. N-Acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res. 1996;56:2683-2687.
58. Debiec-Rychter M, Land SJ, King CM. Tissue-specific expression of human acetyltransferase 1 and 2 detected by non-isotopic in situ hybridization. Proc Am Assoc Cancer Res. 1996;37:133. Abstract.
59. Ross RK, Paganini-Hill A, Henderson BE. Epidemiology of bladder cancer. In: Skinner D, Lieskovsky G, eds. Diagnosis and Management of Genitourinary Cancer. Philadelphia, Pa: WB Saunders Co; 1988:23-31.
60. Mommsen S, Aagaard J. Tobacco as a risk factor in bladder cancer. Carcinogenesis. 1983;4:335-338.
61. Vineis P, Caporaso N, Tannenbaum SR, et al. Acetylation phenotype, carcinogen-hemoglobin adducts and cigarette smoking. Cancer Res. 1990;50: 3002-3004.
62. Yu MC, Skipper PL, Taghizadeh K, et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black and Asian men in Los Angeles, California. J Natl Cancer Inst. 1994;86:712-716.
63. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988; 948:37-66.
64. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet. 1995;4:231-236.
65. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursianinen, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis. 1994;15:813-815.
66. Taylor JA, Umbach D, Stephens E, et al. Role of N-acetylation polymorphism at NAT1 and NAT2 in smoking-associated bladder cancer. Proc Am Assoc Cancer Res. 1995;36:282. Abstract.
67. Josephy PD. The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Mutagenesis. 1996;11:3-7.
68. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995;4:567-571.
69. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991;51:5177-5180.
70. Kaufman DW, Slone D, Rosenberg L, Miettinen OS, Shapiro S. Cigarette smoking and age at natural menopause. Public Health Briefs. 1980;70: 420-422.
71. Lesko SM, Rosenberg L, Kaufman DW, et al. Cigarette smoking and the risk of endometrial cancer. N Engl J Med. 1985;313:593-596.
72. Baron JA. Smoking and estrogen-related disease. Am J Epidemiol. 1984;119:9-22.
73. Ambrosone CB, Freudenheim JL, Graham S, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 1995;55:3483-3485.
74. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci. 1991;99:5237-5241.
75. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther. 1976;19:610-625.
76. Karim AKMB, Elfellah MS, Evans DA. Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution. J Med Genet. 1981;18:325-330.
77. Harris HW, Knight A, Selin MJ. Comparison of isoniazid concentrations in the blood of people of Japanese and European descent: therapeutic and genetic implications. Am Rev Tuberc Pulm Dis. 1958;78:944-948.